Meanwhile, EGCG has demonstrated the ability to inhibit the aggregation of misfolded surfactant protein A2 (SP-A2), proposing a prospective role in mitigating the pathogenesis of lung fibrosis associated with protein aggregation [73]. Here, SFTPA2 is linked to pulmonary fibrosis.